APA (7th ed.) Citation

Chase, D., Eykyn, T. R., Shattock, M. J., & Chung, Y. J. The SGLT2 inhibitor empagliflozin directly increases ketone utilisation in ischaemic hearts independent of substrate supply. Elsevier.

Chicago Style (17th ed.) Citation

Chase, Dylan, Thomas R. Eykyn, Michael J. Shattock, and Yu Jin Chung. The SGLT2 Inhibitor Empagliflozin Directly Increases Ketone Utilisation in Ischaemic Hearts Independent of Substrate Supply. Elsevier.

MLA (9th ed.) Citation

Chase, Dylan, et al. The SGLT2 Inhibitor Empagliflozin Directly Increases Ketone Utilisation in Ischaemic Hearts Independent of Substrate Supply. Elsevier.